New product from Ecolab contamination control to revolutionise the transfer disinfection process
Ecolab Contamination Control, a worldwide provider of leading products and services for the control of microbial contamination in the cleanroom environment, has launched a unique product that will revolutionise the process of transfer disinfection within the pharmaceutical industry (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 26, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Industry News Clean rooms and disinfectant contamination control disinfection process ecolab Latest News Source Type: news
Vectibix® and best supportive care improves overall survival in mCRC
First Phase III Vectibix trial to include a prespecified analysis of efficacy endpoints by RAS tumour status in primary analysis. Results presented at Gastrointestinal Cancers Symposium 2016 reinforce importance of RAS testing (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 25, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Other conferences & symposia Gastroenterology Oncology Patient care Research amgen best supportive care exon 2 gastrointestinal cancers symposium 2016 kras Latest News Source Type: news
Breakthrough drug for heart failure now available in the UK
Novartis drug Entresto™ (sacubitril/valsartan) approved for use in adults with symptomatic chronic heart failure with reduced ejection fraction reduces mortality risk compared with current treatment according to study (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 20, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Cardiovascular medicine Legislation & regulation Patient care British Society for Heart Failure chronic heart failure ejection fraction Entresto HFrEF Latest News mortality risk PARADIGM Source Type: news
Sobi's Orfadin® oral suspension granted European patent
Swedish Orphan Biovitrum AB (publ) (Sobi) announced that the European Patent Office (EPO) has decided to grant a European patent for the Orfadin® (nitisinone) oral suspension formulation (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 19, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Paediatrics Practical therapeutics Legislation & regulation Hepatic disorders Nephrology Patient care hereditary tyrosinaemia type-1 HT-1 Latest News nitisinone oral suspension formulation orfadin Source Type: news
SMC issues positive advice for first ever treatment for ADPKD
JINARC® (tolvaptan) is accepted for use in Scotland for the treatment of autosomal dominant polycystic kidney disease (ADPKD) (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 11, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Legislation & regulation Nephrology Patient care adpkd jinarc Latest News smc tolvaptan Source Type: news
Sobi(TM) announces commercial launch of Elocta® in first countries in Europe
Swedish Orphan Biovitrum AB announced the commercial launch of Elocta® in first countries in Europe (Source: Pharmacy Europe)
Source: Pharmacy Europe - January 11, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Haematology Patient care elocta haemophilia a Latest News recombinant human factor VIII Fc fusion protein Source Type: news
MSD’s KEYTRUDA® significantly improves survival compared to chemotherapy in NSCLC
KEYNOTE-010 published in the Lancet and to be presented at the European Society for Medical Oncology (ESMO) Asia 2015 Congress (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 21, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick European Conferences and Symposia Practical therapeutics Oncology chemotherapy esmo KEYNOTE-010 keytruda Latest News non-small cell lung cancer pembrolizumab Source Type: news
European Commission approves Amgen’s IMLYGIC as first oncolytic immunotherapy in Europe
IMLYGIC is approved in the European Union specifically for early stage metastatic patients (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 18, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Oncology early stage metastic patients herpes simplex type 1 virus IMLYGIC immunotherapy Latest News melanoma Source Type: news
bene-Arzneimittel receives orphan drug status for pentosan polysulphate
Pentosan polysulphate has been awarded the status of an orphan drug from the EMA for the indication of interstitial cystitis (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 18, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick bladder interstitial cystitis Latest News orphan drug pentosan polysulphate Source Type: news
BGMA coordinates patient safety update with MHRA
2600 hospital pharmacies targeted with single set of clear information for patients (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 10, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Association News Generic medicines Patient safety Patient care BGMA hospital pharmacy Latest News mhra Source Type: news
Takeda presents data from Phase III TOURMALINE-MM1 study for NINLARO®
NINLARO® (ixazomib) is the first and only once-weekly oral proteasome inhibitor recently approved for multiple myeloma (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 7, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick ash ixazomib Latest News multiple myeloma NINLARO proteasome inhibitor TOURMALINE-MM1 trial Source Type: news
ESCMID’s EUCAST defining resistance in future antimicrobial agents
EUCAST’s unheralded, but vital work, is helping to ensure responsible use by defining common standards for antimicrobial resistance globally (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 7, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Antimicrobials/AMR Medicines optimisation Harmonisation antimicrobial agents antimicrobial resistance bacteria ecdc ESCMID EUCAST Latest News minimum inhibitory concentration Source Type: news
Dompé’s rhNGF receives orphan drug designation from the EMA
The drug, discovered and developed in Italy, is being studied in patients with neurotrophic keratitis, a pathology still lacking an effective treatment that affects fewer than five out of 10,000 individuals (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 3, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Legislation & regulation Specials orphan drugs Ophthalmology Research cornea eye pathology Latest News neurotrophic keratitis REPARO Phase I/II rhNGF Source Type: news
New Sandoz patient-centric inhaler now available to treat adults with COPD
Novel inhaler approved for adults with chronic obstructive pulmonary disease (COPD) (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 24, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Respiratory Patient care AirFluSal copd fluticasone propionate Forspiro inhaler Latest News salmeterol Seretide Accuhaler treatment adherence Source Type: news
EC approves kyprolis® for combination use in the treatment of relapsed multiple myeloma
First irreversible proteasome inhibitor for relapsed multiple myeloma approved in the European Union (Source: Pharmacy Europe)
Source: Pharmacy Europe - November 20, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Legislation & regulation Oncology ASPIRE trial ENDEAVOR trial kyprolis Latest News protease inhibitor relapsed multiple myeloma Source Type: news
